Gilead Sciences Inc

Latest stories

8d
Business Wire
Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative ColitisFOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today
Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis
Business Wire / Posted 8 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company is stopping its combined Phase 2/3 clinical study of GS-5745, an investigational anti-MMP9 antibody, among patients with moderately to severely... Read more
9d
FOX Business
Allergan To Buy Tobira In Push For Fatty Liver Disease Drugsby the company have potential to reap annual sales of $5 billion. He said expe
Allergan To Buy Tobira In Push For Fatty Liver Disease Drugs
FOX Business / Posted 9 days ago
by the company have potential to reap annual sales of $5 billion. He said experimental NASH drugs being developed by Gilead Sciences Inc have similar sales potential and that treatments being studied by Intercept Pharmaceuticals Inc and... Read more
19 related stories
9d
FOX Business
Allergan To Buy Tobira In Push For Fatty Liver Disease Drugsby the company have potential to reap annual sales of $5 billion. He said expe
Allergan To Buy Tobira In Push For Fatty Liver Disease Drugs
FOX Business / Posted 9 days ago
by the company have potential to reap annual sales of $5 billion. He said experimental NASH drugs being developed by Gilead Sciences Inc have similar sales potential and that treatments being studied by Intercept Pharmaceuticals Inc and... Read more
19 related stories
10d
Market Watch
At $300,000 a year, Sarepta’s new drug is considered a stealtrials,” the company said on a call Monday. But unlike other pricey, new drugs
At $300,000 a year, Sarepta’s new drug is considered a steal
Market Watch / Posted 10 days ago
trials,” the company said on a call Monday. But unlike other pricey, new drugs, including hepatitis C medications such as Gilead Sciences Inc.’s GILD, +3.20% Sovaldi and Harvoni, eteplirsen will likely be a medication DMD patients take for their... Read more
109 related stories
14d
Business Wire
Gilead Prices $5 Billion of Senior Unsecured NotesFOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) today
Gilead Prices $5 Billion of Senior Unsecured Notes
Business Wire / Posted 14 days ago
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ:GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $5 billion, in an underwritten, registered public offering, consisting of five... Read more
2 related stories
14d
Newsmax
Barclays: 33 Stocks That Will Help You Survive Weakening EconomyFinancial Services Group Inc. (HIG) 15. Willis Towers Watson (WLTW) 16. XL Gr
Barclays: 33 Stocks That Will Help You Survive Weakening Economy
Newsmax / Posted 14 days ago
Financial Services Group Inc. (HIG) 15. Willis Towers Watson (WLTW) 16. XL Group Ltd. (XL) 17. Amgen Inc. (AMGN) 18. Gilead Sciences Inc. (GILD) 19. Abbott Laboratories (ABT) 20. Anthem Inc. (ANTM) 21. Cardinal Health Inc. (CAH) 22.... Read more
3 related stories
21d
New Kerala
Hepatitis news .:. Latest News Update on Hepatitischances of committing suicide after being hospitalised with infections like vir
Hepatitis news .:. Latest News Update on Hepatitis
New Kerala / Posted 21 days ago
chances of committing suicide after being hospitalised with infections like viral, according to a new study. Tata Trusts, Gilead sign MoU on viral hepatitis in IndiaNew Delhi, Aug 8 : Tata Trusts has announced signing of an agreement with the... Read more
21d
Swissinfo
Gilead Hires Former Roche Executive to Build China Business(Bloomberg) -- Gilead Sciences Inc. hired a former Roche Holding AG executive t
Gilead Hires Former Roche Executive to Build China Business
Swissinfo / Posted 21 days ago
(Bloomberg) -- Gilead Sciences Inc. hired a former Roche Holding AG executive to build its China commercial operations, preparing for the potential launch of the company’s blockbuster hepatitis drugs in that market over the next few years. Rogers... Read more
21d
Business Wire
AHF: New UCLA Study Shows Gay Men on PrEP Are 45 Times More Likely to Contract Syphilis; 25 Times More Likely To Be Infected With Gonorrheadangerous link between the usage of pre-exposure prophylaxis (PrEP) by men who
AHF: New UCLA Study Shows Gay Men on PrEP Are 45 Times More Likely to Contract Syphilis; 25 Times More Likely To Be Infected With Gonorrhea
Business Wire / Posted 21 days ago
dangerous link between the usage of pre-exposure prophylaxis (PrEP) by men who have sex with men (MSMs) and an astronomical increase in sexually transmitted infections (STIs). “These results by the UCLA researchers add timely, statistical evidence... Read more
2 related stories
23d
Boston Globe
Drug industry group starts ad campaign to defend pricingit saved him from needing a third liver transplant,” one ad says, referring to
Drug industry group starts ad campaign to defend pricing
Boston Globe / Posted 23 days ago
it saved him from needing a third liver transplant,” one ad says, referring to the new hepatitis C treatments developed by Gilead Sciences Inc., AbbVie Inc., and others that have been criticized as too costly. “We want to make the point that these... Read more
2 related stories
24d
Providence Business News
Drug industry group starts ad campaign to push back on pricingit saved him from needing a third liver transplant,” one ad says, referring to
Drug industry group starts ad campaign to push back on pricing
Providence Business News / Posted 24 days ago
it saved him from needing a third liver transplant,” one ad says, referring to the new hepatitis C treatments developed by Gilead Sciences Inc., AbbVie Inc. and others that have been criticized as too costly. “We want to make the point that these... Read more
2 related stories
1m
Profit Confidential
GILD Stock: This Could Be a Big Problem for Gilead Sciences, Inc.GILD Stock: Value Trap? Gilead Sciences, Inc. (NASDAQ:GILD) stock is a heavywe
GILD Stock: This Could Be a Big Problem for Gilead Sciences, Inc.
Profit Confidential / Posted a month ago
GILD Stock: Value Trap? Gilead Sciences, Inc. (NASDAQ:GILD) stock is a heavyweight in the biotech space; the company bolsters a $105.0-billion market cap and ranks high among its competitors like GlaxoSmithKline plc (NYSE:GSK) and Pfizer Inc.... Read more
5 related stories
1m
Salon.com
The footsteps Mylan followed: EpiPens scandal runs deeper than most of us realizeThis article originally appeared on It has been two years since Gilead Science
The footsteps Mylan followed: EpiPens scandal runs deeper than most of us realize
Salon.com / Posted a month ago
This article originally appeared on It has been two years since Gilead Sciences Inc. rolled out its $1,000-a-pill hepatitis C drug Sovaldi, priced at $84,000 for a course of treatment and met with disbelief from patients, insurers and health care... Read more
m
Profit Confidential
GILD Stock: Is This Tiny Company the Next Gilead Sciences, Inc.?The disappointment is compounded when markets are making headway and making new
GILD Stock: Is This Tiny Company the Next Gilead Sciences, Inc.?
Profit Confidential / Posted 1 months ago
The disappointment is compounded when markets are making headway and making new all-time highs. This is my feeling toward Gilead Sciences, Inc. (NASDAQ:GILD) stock. The company is trading at $81.66 and is sitting at the lower end of a trading... Read more
3 related stories

People in this news